Risks of drug prescriptions in elderly people with cardiovascular disease

Authors

  • Marlene García Orihuela Universidad de Ciencias Médicas de La Habana, Facultad de Ciencias Médicas "Calixto García". La Habana, Cuba. https://orcid.org/0000-0001-5666-0874
  • Bárbaro Germán Pérez Hernández Universidad de Ciencias Médicas de La Habana, Facultad de Ciencias Médicas "Calixto García". La Habana, Cuba.
  • Pablo Díaz Hernández Centro de Investigaciones sobre Longevidad, Envejecimiento y Salud (CITED). La Habana, Cuba.

Keywords:

prescription; drug; risk; elderly.

Abstract

Abstract

 

The ageing process brings with it clinical changes, a decrease in the functional reserve of the elderly, psychosocial stressors, frailty and multimorbidity. It also produces pharmacokinetic and pharmacodynamic changes that lead to therapeutic vulnerability with the risk of inappropriate prescriptions.  

Cardiovascular disease is the leading cause of death in this population group, and skill is required to know when to discontinue or replace a drug that may be inappropriate or unsafe. The aim of this review is to analyse a set of prescriptions that may be risky in elderly people with cardiovascular disease. A systematic literature review was conducted to develop a critical reflective analysis of the content of books, documents and original articles from 2014 to 2024. The keywords identified through DECs were: prescription; drug; risk; elderly. Searches were conducted in SciELO, Cochrane Library, PubMed, MEDLINE and Elsevier. The systematisation allowed for the analysis of prescriptions that pose risks to elderly people with cardiovascular diseases.

Downloads

Download data is not yet available.

References

1. Infomed Santiago. (Red de salud de Cuba) [Internet]. Centro de Estudios de Población y Desarrollo. Organización Nacional de Estadísticas e Información (ONEI). El envejecimiento de la población. Cuba y sus territorios: 2022. Santiago de Cuba: ONEI; 2023. [acceso: 13/05/2025]. Disponible en: https://www.sld.cu/el-envejecimiento-de-la-poblacion-cuba-y-sus-territorios-2022/

2. Abreus Mora JL, González Curbelo VB. Fragilidad en adultos mayores y actividad física. Finlay [Internet]. 2023;13(1):111-4. [acceso: 13/05/2025]. Disponible en: http://revfinlay.sld.cu/index.php/finlay/article/view/1235/2215

3. Acosta Benito MA, Martín Lesende I. Fragilidad en atención primaria: diagnóstico y manejo multidisciplinar. Aten Primaria. 2022;54(9):1-9. [acceso: 13/05/2025]. Disponible en: https://dialnet.unirioja.es/servlet/articulo?codigo=8563619

4. Khunti K, Sathanapally H, Mountain P. Multiple long term conditions, multimorbidity, and comorbidities: we should reconsider the terminology we use. BMJ. [Internet]. 2023;383:2327. [access: 13/05/2025]. Available from: https://doi.org/10.1136/bmj.p2327

5. K Inouye S, Studenski S, E Tinetti M, A Kuchel G. Síndromes geriátricos: implicaciones clínicas, de investigación y políticas de un concepto geriátrico central. J Am Geriatr Soc. [Internet]. 2007;55(5):780-91. [access: 7/08/2025]. Disponible en: https://doi.org/10.1111/j.1532-5415.2007.01156.x

6. Bertram G Katzund Chapter 60 Special Aspects of Geriatric Pharmacology. In: Basic & Clinical Pharmacology. 15 th edition. New York: McGraw-Hill Education; 2021. p. 1578-92. [access: 13/05/2025]. Available from: https://accessmedicine.mhmedical.comcontent.aspx?bookid=2988&sectionid=250604555

7. Olmos I, Angulo D, Mato M, Ricciardi C, Toledo M, Vázquez M. Seguridad del paciente: análisis de la prescripción en adultos mayores de una policlínica de salud mental del Hospital Vilardebó, Uruguay. Rev Med Urug [Internet]. 2022;38(4): e38404. [acceso: 19/05/2025]. Disponible en: http://doi.org/10.29193/rmu.38.4.3

8. Beers MH. Explicit criteria for determining potentially inappropriate medication use by the elderly: An update. Arch Intern Med [Internet]. 1997;157:1531-36. [access: 19/05/2025]. Available from: https://pubmed.ncbi.nlm.nih.gov/9236554/

9. American Geriatrics Society (AGS). 2019 Updated AGS Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc [Internet]. 2019;67(4):674-94. [access: 19/05/2025]. Available from: https://doi.org/10.1111/jgs.15767

10. Todd A, Husband A, Andrew I, Pearson SA, Lindsey L and Holmes H. Inappropriate prescribing of preventative medication in patients with life-limiting illness: a systematic review. BMJ Support Palliat Care [Internet]. 2017;7(2):113-21. [access: 20/05/2025]. Available from: https://dx.doi.org/10.1136/bmjspcare-2015-000941

11. Shrestha S, Poudel A, Steadman KJ, Nissen LM. Deprescribing tool for use in older Australians with life-limiting illnesses and limited life expectancy: a modified-Delphi study protocol. BMJ Open [Internet]. 2021;11:e043766. [access: 20/05/2025]. Available from: https://bmjopen.bmj.com/33795304/

12. Curtin D, Gallagher P, O' Mahony D. Deprescribing in older people approaching end-of-life: development and validation of STOPP Frail version 2. Age and Ageing [Internet]. 2020;50(2):465-471. [access: 21/05/2025]. Available from: https://doi.org/10.1093/ageing/afaa159

13. Anuario Estadístico de la Salud Cuba 2023. Dirección de Registros Médicos y Estadísticas de Salud. MINSAP. [Internet]. 2024:50-70. [acceso: 21/05/2025]. Disponible en: https://files.sld.cu/dne/files/2024/09/Anuario-Estad%c3%adstico-de-Salud-2023-EDICION-2024.pdf

14. García Orihuela M, Suárez Martínez R, Pérez Hernández B. Criterios STOPP-START y la prescripción inapropiada del anciano. Rev Haban Cienc Méd [Internet]. 2020;19(6):e3765. [acceso: 21/05/2025]. Disponible en: http://www.revhabanera.sld.cu/index.php/rhab/article/view/3765

15. Pacheco Ballester D, Ortiz Sánchez Y, Guerrero Ballester Y, Gómez Padilla O, Fernández Corrales YN. Polifarmacia y prescripción de medicamentos potencialmente no apropiados en adultos mayores hospitalizados. Multimed [Internet]. 2023;(27):e2690. [acceso: 21/05/2025]. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_aettext&pid=S102848182023000100006

16. Cruz Jentoft AJ. Prescripción inapropiada de medicamentos en personas mayores. An RANM. [Internet]. 2022;139(02):121-7. [acceso: 24/05/2025]. Disponible en: https://analesranm.es/revista/2022/139_02/13902_rev01

17. Zamorano P, Muñoz P, Espinosa M, Tellez A, Varela T, Suárez F, et al. Impact of a high-risk multimorbidity integrated care implemented at the public health system in Chile. PLoS One. [Internet]. 2022;17(1):e0261953. [access: 24/05/2025]. Available from: https://dx.doi.org/10.1371/journal.pone.0261953

18. Huaquía Díaz AM, ChalánDávila TS, Carrillo Larco RM, Bernabé Ortiz A. Multimorbidity in Latin America and the Caribbean: a systematic review and meta-analysis. BMJ Open. [Internet]. 2021;11(7):e050409. [access: 24/05/2025]. Available from: https://doi.org/10.1136/bmjopen-2021-050409

19. Nicholson K, Liu W, Fitzpatrick D, Hardacre KA, Roberts S, Salermo J, et al. Prevalence of multimorbidity and polypharmacy among adults an older adults: a systematic review. Lancet Health Long. [Internet]. 2024;5:e287-96. [access: 24/05/2025]. Available from: https://doi.org/10.1016/S2666-7568(24)00007-2

20. Cristofori G, Lozano Montolla I, Baztán Cortés JJ. Síndromes geriátricos: aspectos fisiopatológicos, clínicos y terapéuticos comunes. En: Abizanda Soler P, Rodríguez Mañas L, Baztán Cortés JJ. Tratado de Medicina Geriatría. Fundamentos de la atención sanitaria a los mayores. 2a. ed. Madrid: Elsevier; 2020. p. 651-7. [acceso: 24/05/2025]. Disponible en: https://investigacion.uax.com/documentos/6480cac60584525450ed3de0

21. Parada Peña K, Rodríguez Morena M, Otoya Chaves F, Loaiza Quirós K, León Quirós S. Síndromes geriátricos: caídas, incontinencia y deterioro cognitivo. Rev Hisp Cienc Salud. [Internet]. 2020; 6(4):201-10. [acceso: 24/05/2025]. Disponible en: https://dialnet.unirioja.es/revhispano/article/ciwe/450

22. Pérez Pavón A, Villegas Villegas A, López Franco YS, Casas Patiño D, Rodríguez Torres A. Síndromes geriátricos y abandono. Rev Finlay [Internet]. 2023;13(4):386-93. [aprox. 6 p.]. [acceso: 24/05/2025]. Disponible en: http://scielo.sld.cu/index.php/finlay/article/view/1292

23. Figueroa MR, Aguirre DP, Hernández RR. Asociación del deterioro cognitivo, depresión, redes sociales de apoyo, miedo y ansiedad a la muerte en adultos mayores. PSICUMEX. [Internet]. 2021;11(397):2-29. [aprox. 6 p.]. [acceso: 26/05/2025]. Disponible en: https://psicumex.unison.mx/index.php/psicumex/article/view/397/3149

24. Zehnder JL. Chapter 34 Drugs used in disorders of coagulation. In: Katzung BG. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021. p. 909-935. [access: 27/05/2025]. Available from: https://accessmedicine.mhmedical.com/content.aspx?bookid=2988&sectiond=250599717

25. Vega AJ, Smith C, Matejowsky HG, Thornhill KJ, Borne GE, Mosieri CN, et al. Warfarin and antibiotics: Drug interactions and clinical considerations. Life [Internet]. 2023;13(8):1661. [access: 27/05/2025]. Available from: https://doi.org/10.3390/life13081661

26. Patel S, Singh R, Preuss CV, Patel N. Warfarina. [Updated 2024 Oct 5]. In: Stat Pearls. Treasure Island (FL): Stat Pearls Publishing; Jan 2025. [access: 27/05/2025]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470313/

27. Fu EL, Desai RJ, Paik JM, Kim DH, Zhang Y, Mastrorilli JM, et al. Comparative safety and effectiveness of warfarin or rivaroxaban versus apixaban in patients with advanced CKD and atrial fibrillation: Nationwide US Cohort Study. Am J Kidney Dis [Internet]. 2024;83(3):293-305. [access: 27/05/2025]. Available from: https://doi.org/10.1053/j.ajkd.2023.08.017

28. Benowitz NL. Chapter 11 Antyhipertensive agents. In: Katzung BG. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021. p. 254-85. [access: 29/05/2025]. Available from: https://accessmedicine.mhmedical.com/content.aspx?bookid=2988&sectiond=250595338

29. Cochrane library.com. [Internet]. (Chile). Reeve E, Jordan V, Thompson W, Sawan M, Tood A, Gammie TM, et al. Withdrawal of antihypertensive drugs in older people. Cochrane Database Syst Rev. 2020. [access: 09/01/2025]. Copyright©2000-2025 JohnWiley & Sons, Inc. Available from: http://cochranelibrary.com/cdsr/doi/10.1002/14651858.CDO12572.pub2/full

30. Leyva López Y, Torres Peláez ML, Guerrero Barrera A, Padilla Flores I. Validación de la idoneidad de la prescripción médica en pacientes cardiópatas. Arch Cardiol Mex. [Internet]. 2021;92(1):75-84. [acceso: 09/06/2025]. Disponible en: https://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S1405994020220000100075Ing=es

31. Katzung BG. Chapter 13 Drugs used in heart failure. In: Katzung BG. Basic & Clinical Pharmacology. 15th edition. New York: McGraw-Hill Education; 2021. p. 315-37. [access: 09/06/2025]. Available from: https://accessmedicine.mhmedical.com/content.aspx?bookid=2988&sectiond=250595741

32. Roselló Azcanio Y, Alzate Berrio C, Rojas Gutiérrez A, Chao Pereira C. Comportamiento de comorbilidades en la mortalidad de pacientes con insuficiencia cardiaca crónica. Rev Cub Med. [Internet]. 2021;60(3):e2059. [acceso: 09/06/2025]. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S003475232021000300013&Ing=es

33. Katzung BG. Chapter 12 Vasodilators & the Treatment of Angina Pectoris. In: Katzung BG. Basic & Clinical Pharmacology. 14th ed. New York: McGraw-Hill Education; 2021. p. 286-314. [access: 10/06/2025]. Available from: https://accessmedicine.mhmedical.com/content.aspx?bookid=2988&sectiond=250595578

34. Harvey RD, Grant AO. Chapter 14 Agents used in cardiac arrhythmias. In: Katzung BG. Basic & Clinical Pharmacology. 14th edition. New York: McGraw-Hill Education; 2021. p. 338-75. [access: 10/06/2025]. Available from: https://accessmedicine.mhmedical.com/content.aspx?bookid=2988&sectiond=250595882

35. Malloy MJ, Kane JP. Chapter 35 Agents used in dyslipidemias. In: Katzung BG. Basic & Clinical Pharmacology. 14th ed. New York: McGraw-Hill Education; 2021. p. 936-959. [access: 10/06/2025]. Available from: https://accessmedicine.mhmedical.com/content.aspx?bookid=2988&sectiond=250599916

36. Drasner K. Chapter 26 Local anesthetics. In: Katzung BG. Basic & Clinical Pharmacology. 14th ed. New York: McGraw-Hill Education; 2021. p. 679-701. [access: 10/06/2025]. Available from: https://accessmedicine.mhmedical.com/content.aspx?bookid=2988&sectiond=250598245

37. Bhakta NR, Choo E. Chapter 20 Drugs used in asthma & chronic obstructive pulmonary disease. In: Katzung BG. Basic & Clinical Pharmacology. 14th ed. New York: McGraw-Hill Education; 2021. p. 521-48. [access: 10/065/2025]. Available from: https://accessmedicine.mhmedical.com/content.aspx?bookid=2988&sectiond=250597179

38. Shagroni T, Cazares R, Kim JA, Furst DE. Chapter 36 Nonsteroidal anti-inflammatory drugs, disease-modifying antirheumaty drugs nonopioid analgesics, & drugs used in gout. In: Katzung BG. Basic & Clinical Pharmacology. 14th ed. New York: McGraw-Hill Education; 2021. p. 960-92. [access: 10/06/2025]. Available from: https://accessmedicine.mhmedical.com/content.aspx?bookid=2988&sectiond=250600111

39. Sam R, Pearce D. Chapter 15 Diuretic agents. In: Katzung BG. Basic & Clinical Pharmacology. 14th ed. New York: McGraw-Hill Education; 2021. p. 376-413. [access: 10/06/2025]. Available from: https://accessmedicine.mhmedical.com/content.aspx?bookid=2988&sectiond=250596112

40. Chrousos GP. Chapter 39 Adrenocorticosteroids & adrenocortical antagonists. In: Katzung BG. Basic & Clinical Pharmacology. 14th ed. New York: McGraw-Hill Education; 2021. p. 1051-74. [access: 10/06/2025]. Available from: https://accessmedicine.mhmedical.com/content.aspx?bookid=2988&sectiond=250600694

41. De Battista C. Chapter 30 Antidepressant agents. In: Katzung BG. Basic & Clinical Pharmacology. 14th ed. New York: McGraw-Hill Education; 2021. p. 792-826. [access: 10/06/2025]. Available from: https://accessmedicine.mhmedical.com/content.aspx?bookid=2988&sectiond=250598963

42. Aminoff MJ. Chapter 28 Pharmacology management of parkinsonism & other movement disorders. In: Katzung BG. Basic & Clinical Pharmacology. 14th ed. New York: McGraw-Hill Education; 2021. p. 731-59. [Access: 10/06/2025]. Available from: https://accessmedicine.mhmedical.com/content.aspx?bookid=2988&sectiond=250598520

43. Dong BJ. Chapter 38 Thyroid & antithyroid drugs. In: Katzung BG. Basic & Clinical Pharmacology. 14th ed. New York: McGraw-Hill Education; 2021. p. 1023-50. [access: 10/06/2025]. Available from: https://accessmedicine.mhmedical.com/content.aspx?bookid=2988&sectiond=250600512

44. Chrousos GP. Chapter 40: The gonadal hormones & inhibitors. In: Katzung BG. Basic & Clinical Pharmacology. 14th ed. New York: McGraw-Hill Education; 2021. p. 1075-118. [access: 10/06/2025]. Available from: https://accessmedicine.mhmedical.com/content.aspx?bookid=2988&sectiond=250600884

Downloads

Published

2025-08-23

How to Cite

1.
García Orihuela M, Pérez Hernández BG, Díaz Hernández P. Risks of drug prescriptions in elderly people with cardiovascular disease. Arch Hosp Univ "Gen Calixto García” [Internet]. 2025 Aug. 23 [cited 2025 Aug. 26];13(2). Available from: https://revcalixto.sld.cu/index.php/ahcg/article/view/1580

Issue

Vol. 13 No. 2 (2025): Mayo - Agosto ... (en progreso)

Section

Artículos de Revisión

License

Copyright (c) 2025 Marlene García Orihuela, Bárbaro Germán Pérez Hernández, Pablo Díaz Hernández

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:

  1. Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia Creative Commons Atribución– No Comercial 4.0 que permite el uso, distribución y reproducción no comerciales y sin restricciones en cualquier medio, siempre que sea debidamente citada la fuente primaria de publicación.
  2. Los autores/as podrán adoptar otros acuerdos de licencia no exclusiva de distribución de la versión de la obra publicada (p. ej.: depositarla en un archivo telemático institucional o publicarla en un volumen monográfico) siempre que se indique la publicación inicial en esta revista.
  3. Se permite y recomienda a los autores/as difundir su obra a través de Internet (p. ej.: en archivos telemáticos institucionales o en su página web) antes y durante el proceso de envío, lo cual puede producir intercambios interesantes y aumentar las citas de la obra publicada.